Publications
2026
Initial Clinical Experience with [177Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry
Journal of Nuclear Medicine, 2026
Lisa Glantschnig, Johanna S. Enke, Bradley W. Schuller, Eric J. Fenn, Alexander Dierks, Marianne Patt, Andreas Rinscheid, Robert Seifert, Lena M. Unterrainer, Lars H. Lindner, Dorit Di Gioia, John W. Babich, Alejandro Amor Coarasa, Matthias Friebe, Jacob Y. Hesterman, Ralph A. Bundschuh, Constantin Lapa
Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [68Ga]Ga-LNTH-1363S on Image Quality
Journal of Nuclear Medicine, 2026
Johanna S. Enke, Jan Baessler, Gitasha Chand, Lisa Glantschnig, Bing Bai, Karl Sjoestrand, Martin Trepel, Kelly Orcutt, Niklas Dreher, Marianne Patt, Alexander Dierks, Constantin Lapa
2025
Biodistribution and Radiation Dosimetry for [68Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein α
Journal of Nuclear Medicine, August 2025; 66(8):1284–1290
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
2024
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
Journal of Clinical Oncology, May 2024; 42(15):1734–1737
Ana P. Kiess, Joseph O’Donoghue, Carlos Uribe, Lisa Bodei, Robert F. Hobbs, Jacob Hesterman, Adam L. Kesner, George Sgouros; RPT-TEC Group
2023
Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements
PET Clinics, July 2023; 18(3):287–294
Stephen G. DiMagno, John W. Babich